Get started
Work

Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial

Year: 2024
Type: article
Abstract: This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.
DOI: 10.2337/cd24-0003
Authors: Vojtěch Melenovský, Eva Hošková, Kateřina Velebová, Jiří Veleba, Barry A. Borlaug, Jan Benes, Ondřej Kuda, Tomáš Čajka, Markéta Segeťová, Lenka Thieme, Jan Kopecký, Jan Kopecký, Terezie Pelikánová, Martin Haluzík, Martin Hill, Hana Kahleová
Institutions: Institute of Clinical and Experimental Medicine, Mayo Clinic, Czech Academy of Sciences, Czech Academy of Sciences, Institute of Physiology, Institute of Endocrinology, Physicians Committee for Responsible Medicine
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4402349619
FWCI: 1.617
Cites: 33
Cited by: 6
Related to: 10